MX2022013595A - Metodos de uso de moduladores del canal de calcio tipo t. - Google Patents

Metodos de uso de moduladores del canal de calcio tipo t.

Info

Publication number
MX2022013595A
MX2022013595A MX2022013595A MX2022013595A MX2022013595A MX 2022013595 A MX2022013595 A MX 2022013595A MX 2022013595 A MX2022013595 A MX 2022013595A MX 2022013595 A MX2022013595 A MX 2022013595A MX 2022013595 A MX2022013595 A MX 2022013595A
Authority
MX
Mexico
Prior art keywords
calcium channel
type calcium
methods
channel modulators
seizures
Prior art date
Application number
MX2022013595A
Other languages
English (en)
Spanish (es)
Inventor
Kiran Reddy
Bernard Ravina
Marion Wittmann
Gabriel Belfort
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of MX2022013595A publication Critical patent/MX2022013595A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transmitters (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2022013595A 2020-04-29 2021-04-28 Metodos de uso de moduladores del canal de calcio tipo t. MX2022013595A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063017140P 2020-04-29 2020-04-29
US202063050410P 2020-07-10 2020-07-10
US202063082946P 2020-09-24 2020-09-24
PCT/US2021/029539 WO2021222342A1 (en) 2020-04-29 2021-04-28 Methods of use of t-type calcium channel modulators

Publications (1)

Publication Number Publication Date
MX2022013595A true MX2022013595A (es) 2023-01-24

Family

ID=78373913

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013595A MX2022013595A (es) 2020-04-29 2021-04-28 Metodos de uso de moduladores del canal de calcio tipo t.

Country Status (11)

Country Link
US (1) US12697331B2 (cg-RX-API-DMAC7.html)
EP (1) EP4142764A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023524039A (cg-RX-API-DMAC7.html)
KR (1) KR20230018384A (cg-RX-API-DMAC7.html)
CN (1) CN115776894A (cg-RX-API-DMAC7.html)
AU (1) AU2021263804A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021946A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177277A1 (cg-RX-API-DMAC7.html)
IL (1) IL297642A (cg-RX-API-DMAC7.html)
MX (1) MX2022013595A (cg-RX-API-DMAC7.html)
WO (1) WO2021222342A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021007487A1 (en) 2019-07-11 2021-01-14 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof
CA3243616A1 (en) * 2022-02-03 2023-08-10 Praxis Precision Medicines, Inc. TREATMENT METHODS USING T-TYPE CALCIUM CHANNEL MODULATORS
WO2023192885A2 (en) * 2022-03-28 2023-10-05 Praxis Precision Medicines, Inc. Methods of using oligomeric compounds to treat scn2a-related disorders
US20250295646A1 (en) * 2022-05-09 2025-09-25 Praxis Precision Medicines, Inc. Methods of use of t-type calcium channel modulators
CN121127457A (zh) * 2023-03-02 2025-12-12 普拉西斯精密医药公司 T型钙通道调节剂的结晶盐和其使用方法
AU2024230578A1 (en) * 2023-03-02 2025-09-04 Praxis Precision Medicines, Inc. Crystalline salt forms of n-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide and methods of use thereof
WO2025059511A1 (en) 2023-09-15 2025-03-20 Praxis Precision Medicines, Inc. Elsunersen / prax-222 for use in the treatment of scn2a-related disorders
WO2025188619A1 (en) * 2024-03-04 2025-09-12 Praxis Precision Medicines, Inc. Methods of treating parkinson's disease with t-type calcium channel modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377968B2 (en) * 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
EP3364993B1 (en) * 2015-10-22 2022-11-09 Cavion, Inc. Methods for treating angelman syndrome
RU2746188C2 (ru) * 2015-11-12 2021-04-08 Афаски, Инк. Ингибиторы ионного канала, фармацевтические составы и применение
HRP20220463T1 (hr) * 2016-12-16 2022-05-27 Idorsia Pharmaceuticals Ltd Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa
WO2018118101A1 (en) * 2016-12-21 2018-06-28 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof
SG11202004329TA (en) * 2017-11-10 2020-06-29 Marinus Pharmaceuticals Inc Ganaxolone for use in treating genetic epileptic disoders
JP7480131B2 (ja) * 2018-10-03 2024-05-09 カビオン・インコーポレイテッド (r)-2-(4-イソプロピルフェニル)-n-(1-(5-(2,2,2-トリフルオロエトキシ)ピリジン-2-イル)エチル)アセトアミドを使用した本態性振戦の処置
WO2021007487A1 (en) * 2019-07-11 2021-01-14 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof
US20250295646A1 (en) * 2022-05-09 2025-09-25 Praxis Precision Medicines, Inc. Methods of use of t-type calcium channel modulators

Also Published As

Publication number Publication date
AU2021263804A1 (en) 2023-01-19
CN115776894A (zh) 2023-03-10
IL297642A (en) 2022-12-01
JP2023524039A (ja) 2023-06-08
BR112022021946A2 (pt) 2023-01-17
US12697331B2 (en) 2026-08-04
KR20230018384A (ko) 2023-02-07
JP2026127654A (ja) 2026-08-06
CA3177277A1 (en) 2021-11-04
EP4142764A1 (en) 2023-03-08
EP4142764A4 (en) 2024-05-29
WO2021222342A1 (en) 2021-11-04
US20230165847A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
BR112022021946A2 (pt) Métodos de uso de moduladores do canal de cálcio do tipo t
BR112022000429A2 (pt) Formulações de moduladores do canal de cálcio tipo t e métodos de uso dos mesmos
MX2025001282A (es) Moduladores de los canales ionicos
MX2021003634A (es) Moduladores de canales de iones.
MX2022006317A (es) Moduladores de canales iónicos.
EA202190369A1 (ru) Способ лечения эпилепсии
BR112021016620A2 (pt) Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
MX2025005941A (es) Moduladores de la actividad tnf-\03b1
EP4671248A3 (en) Formulations of ion channel modulators and methods of preparation and use of ion channel modulators
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
JOP20230036A1 (ar) نواهض مستقبل أوريكسين بيروليدين سيكلوهيبتان
MX2021011488A (es) Compuestos y usos de estos.
WO2025188619A8 (en) Methods of treating parkinson's disease with t-type calcium channel modulators
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
BR112022003959A2 (pt) Métodos para tratamento de epilepsia
BR112021006398A2 (pt) tratamento de tremor essencial usando (r)-2-(4-isopropilfenil)-n-(1-(5-(2,2,2-trifluoretoxi)piridin-2-il)etil) acetamida
ZA202210888B (en) Mtorc1 modulators and uses thereof
MX2023012834A (es) Inhibidor de la matriptasa-2 para el tratamiento de trastornos mieloproliferativos.
WO2019165158A8 (en) Il-6 inhibitors and methods of treatment
MX2023014061A (es) Degradadores de receptor del factor de crecimiento epidérmico para tratar metástasis de cáncer al cerebro o sistema nervioso central.
MX2022003134A (es) Administracion intranasal de esketamina.
PH12020551179A1 (en) Methods for treating mitochondrial disorder
MX2025011864A (es) Potenciadores de kcc2 y usos de estos
WO2021157939A3 (ko) Saha를 유효성분으로 포함하는 뇌질환 예방 또는 치료용 조성물
MX2022011888A (es) Tratamiento de trastornos respiratorios.